Considering the growing interest in Banerji protocol remedies among patients at the M.D. Anderson Cancer Center of the University of Texas, most of whom have advanced breast cancer, a team of researchers decided to evaluate the in-vitro effect of those remedies.
The result of this study has just been published in the International Journal of Oncology. The study has demonstrated that four ultra-diluted homeopathic medicines exerted preferential cytotoxic effects against two breast cancer cell lines (MCF-7 and MDA-MB-231), causing cell cycle delay/arrest and apoptosis. These effects were accompanied by altered expression of the cell cycle regulatory proteins, including downregulation of phosphorylated Rb and upregulation of the CDK inhibitor p27, which were likely responsible for the cell cycle delay/arrest as well as induction of the apoptotic cascade that manifested in the activation of caspase 7 and cleavage of PARP in the treated cells.
The experiments were conducted in triplicate and repeated at least twice in each case of remedy. The researchers commented that the homeopathic remedies appeared to have similar activity to the activity of paclitaxel (Taxol), the most commonly used chemotherapeutic drug for breast cancer, without the toxic effect on the normal cells. The findings demonstrate biological activity of these products when presented at ultra-diluted doses.
References:
Banerji P, Campbell DR (2008): Cancer patients treated with the Banerji protocols utilising homoeopathic medicine: A Best Case Series Program of the National Cancer Institute USA. Oncology Reports, 20: 69-74.
To be downloaded here.
Frenkel M et al. (2010): Cytotoxic effects of ultra-diluted remedies on breast cancer cells. International Journal of Oncology, 36: 395-403.
To be downloaded here.